Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer

Hepato-Gastroenterology

Volumn 54, Issue 79, 2007, Pages 1934-1940

  Meng, Hua ^a   Tanigawa, Nobuhiko ^b   Hao, Chun Yi ^a   Dai, De Jian ^c   Lu, Cai De ^d   Ji, Jia Fu ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d NINGBO UNIVERSITY   (China)

Author keywords

Drug response; Gastric cancer; Real time quantitative RT PCR; Survivin splicing variants

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; MESSENGER RNA; MITOMYCIN C; OLIGONUCLEOTIDE; SURVIVIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOMARKERS, PHARMACOLOGICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN SPLICING; ROC CURVE; STOMACH NEOPLASMS; TAXOIDS; VARIATION (GENETICS);

EID: 37749018872     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kohnoe S, Maehara Y, Takahashi I, Emi Y, Baba H, Sugimachi K: Treatment of advanced gastric cancer with 5-fluorouracil and cisplatin in combination with dipyridamole. Int J Oncol 1998; 13:1203-1206.
2. Ikeguchi M, Liu J, Kaibara N: Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 2002; 7:23-29.
3. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H: Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods 1998; 37:105-116.
4. Yu J, Leung WK, Ebert MP, Ng EK, Go MY, Wang HB, Chung SC, Malfertheiner P, Sung JJ: Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 2002; 87:91-97.
5. Huschtscha LI, Bartier WA, Ross CE, Tattersall MH: Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 1996; 73:54-60.
6. Nomura T, Yamasaki M, Nomura Y, Mimata H: Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005; 14:993-997.
7. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F: Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003; 55:1341-1347.
8. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54.
9. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002; 20:1063-1068.
10. Altieri DC: Survivin and apoptosis control. Adv Cancer Res 2003; 88:31-52.
11. Zaffaroni N, Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002; 5:65-72.
12. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59:1406-1412.
13. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59:6097-6102.
14. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma, First English edition. Tokyo: Kaneha & Co., Ltd., 1995.
15. Ariyoshi Y, Shimahara M, Tanigawa N: Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 2003; 39:701-707.
16. Furukawa T, Kubota T, Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1:305-311.
17. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M, et al: High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 1992; 51:489-498.
18. Suda S, Akiyama S, Sekiguchi H, Kasai Y, Ito K, Nakao A: Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 2002; 32:477-481.
19. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K, Miyatake S: Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003; 99:738-745.
20. Meng H, Lu C, Mabuchi H, Tanigawa N: Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 2004; 216:147-155.
21. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
22. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin, Nature 1998; 396:580-584.
23. Chen JG, Yang CP, Cammer M, Horwitz SB: Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003; 63:7891-7899.
24. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51:4845-4852.
25. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83:288-291.
26. Li F, Altieri DC: The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59:3143-3151.
27. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002; 62;2462-2467.
28. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH: Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. Embo J 2003; 222:934-2947.
29. Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev 1974; 1:285-304.
30. Perry MC, Green MR, Mick R, Schein P: Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study. Cancer Treat Rep 1986; 70:415-416.
31. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G: Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 2003; 23:4219-4222.
32. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62:2695-2698.